Sleep Disorders Trial, Recruiting NCT03954899 Sponsor: Natalie Denburg Condition: Sleep Disorders
Back to Sleep Disorders

Sleep Disorders Trial, Recruiting

NCT03954899
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between the ages of 56 and 85 years old
  • People who score 18 or above on a memory and thinking test called the Montreal Cognitive Assessment (MoCA)
  • People whose level of daily functioning is not significantly affected by memory problems, as measured by a standard rating scale called the Clinical Dementia Rating (CDR) — specifically, a total score below 1 (confirm with trial site)
  • People who are willing to have two blood draws for biomarker testing over the course of the study (note: as of August 2024, the spinal fluid collection procedures previously part of this trial have been removed)
  • People who are willing and able to stop using prescription or non-prescription sleep aids — such as Ambien, Melatonin, Lunesta, or similar products — for the entire duration of the study, except for any medications provided by the study
  • People with a Body Mass Index (BMI) below 35 at the time of joining the study
  • People who are willing to bring a spouse, child, or close friend who knows them well to each of the four study visits

Who may not be able to join:

  • People who have sleep apnea and do not use a CPAP machine, or who have chronic lung conditions such as COPD or emphysema
  • People with a major psychiatric diagnosis such as bipolar disorder or schizophrenia
  • People with a history of alcohol or drug abuse
  • People diagnosed with a brain or nervous system condition such as Parkinson's disease, Lewy body disease, ALS, or multiple sclerosis
  • People who have previously had a stroke or a traumatic brain injury
  • People who have undergone chemotherapy in the past 2 years
  • People who have been hospitalised for an injury or surgery in the past 3 months
  • People whose CDR score is 1 or higher, or who have clinically significant depression or anxiety as measured by standard rating scales (confirm with trial site)
  • People currently taking any of the following types of medication: Fluvoxamine (Luvox) or Fluoxetine (Prozac); Nifedipine (a blood pressure medication); blood thinners such as Warfarin, Xarelto, or Heparin; anti-seizure medications such as Gabapentin or Carbamazepine; muscle relaxants such as Valium or Baclofen; or narcotic pain relievers such as Codeine, Tramadol, or Hydrocodone

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Natalie Denburg, Ph.D., University of Iowa

Phone: 3193846050

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Natalie Denburg
Registry
ClinicalTrials.gov
Start date
12 November 2019
Est. completion
1 November 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Episodic memory

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov